Mikie: A randomized, double-blinded, regimen-controlled, phase 2 study to assess the efficacy and safety of two different vismodegib (VISMO) regimens in patients (pts) with multiple basal cell carcinomas (BCCs).

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Oncology

• Publication date

  2016-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2016.34.15_SUPPL.9509
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Hedgehog signalling pathway inhibitors in the treatment of basal cell carcinoma: an updated review

  2025cites this paper
• Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin

  2018cites this paper
• Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases

  2017cites this paper
• Non-melanoma skin cancer: new and future synthetic drug treatments

  2017cites this paper
• Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

  2016cites this paper
• Hedgehog pathway inhibitor therapy in basal-cell nevus syndrome.

  2016cites this paper